Aclaris Therapeutics, Inc. (ACRS) Dividend History

Company News

• Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

  Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results and provided a corporate update. The company's CEO and senior leadership team will participate in a virtual fireside chat.

  GlobeNewswire Inc.
• Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

  Aclaris Therapeutics, a clinical-stage biopharmaceutical company, has appointed Jesse Hall, M.D. as its new Chief Medical Officer. Dr. Hall's extensive experience in areas like immunology and antibody development will be crucial in leading Aclaris' clinical strategy for its portfolio of immuno-inflammatory product candidates.

  GlobeNewswire Inc.
• JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight

  The article discusses the robust pipeline of JAK inhibitors, with over 50 key pharmaceutical companies actively working on developing new drugs in this therapeutic segment. The pipeline includes promising JAK inhibitors in various stages of clinical trials, targeting a range of autoimmune disorders and cancer.

  GlobeNewswire Inc.

  Featured Companies: PFE
• Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

  Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced that members of its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference.

  GlobeNewswire Inc.
• Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying - Benzinga

  Insiders have been buying shares in several penny stocks, including Branchout Food, Innovative Food Holdings, Crown Equity Holdings, and Aclaris Therapeutics. The insider purchases indicate their confidence in the companies' prospects.

  Benzinga

  Featured Companies: BOF